Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Spector

Showing results (871-880 of 939) with videos related to

Pageof 94
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|October 11, 2008
Associations of chemokine receptor polymorphisms With HIV-1 mother-to-child transmission in sub-Saharan Africa: possible modulation of genetic effects by antiretroviralsKumud K Singh, Michael D Hughes, Jie Chen, et al.
The Pediatric Infectious Disease Journal|October 12, 2011
Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected childrenGeorge K Siberry, Meredith G Warshaw, Paige L Williams, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 28, 2014
Raltegravir pharmacokinetics in neonates following maternal dosingDiana F Clarke, Edward P Acosta, Matthew L Rizk, et al.
Annals of Internal Medicine|December 4, 2001
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320L M Demeter, M D Hughes, R W Coombs, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 23, 2013
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 yearsSharon Nachman, Nan Zheng, Edward P Acosta, et al.
The Journal of Infectious Diseases|December 29, 2020
Genomics Links Inflammation With Neurocognitive Impairment in Children Living With Human Immunodeficiency Virus Type-1Pratima Rawat, Sean S Brummel, Kumud K Singh, et al.
Annals of Internal Medicine|June 15, 1997
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy TeamM D Hughes, V A Johnson, M S Hirsch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 9, 2020
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110)Diana F Clarke, Edward P Acosta, Mae Cababasay, et al.
Hepatology (Baltimore, Md.)|September 10, 2024
Association of HDV infection and HCC, hepatic decompensation, and all-cause and liver-related death in a national cohortBinu V John, Dustin Bastaich, Mahmoud Manouchehri Amoli, et al.
The Journal of Infectious Diseases|June 25, 2004
Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapyPatricia M Flynn, Bret J Rudy, Steven D Douglas, et al.
Pageof 94

Showing results (871-880 of 939) with videos related to

Sort By:
Pageof 94
Journal of Acquired Immune Deficiency Syndromes (1999)|October 11, 2008
Associations of chemokine receptor polymorphisms With HIV-1 mother-to-child transmission in sub-Saharan Africa: possible modulation of genetic effects by antiretroviralsKumud K Singh, Michael D Hughes, Jie Chen, et al.
The Pediatric Infectious Disease Journal|October 12, 2011
Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected childrenGeorge K Siberry, Meredith G Warshaw, Paige L Williams, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 28, 2014
Raltegravir pharmacokinetics in neonates following maternal dosingDiana F Clarke, Edward P Acosta, Matthew L Rizk, et al.
Annals of Internal Medicine|December 4, 2001
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320L M Demeter, M D Hughes, R W Coombs, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 23, 2013
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 yearsSharon Nachman, Nan Zheng, Edward P Acosta, et al.
The Journal of Infectious Diseases|December 29, 2020
Genomics Links Inflammation With Neurocognitive Impairment in Children Living With Human Immunodeficiency Virus Type-1Pratima Rawat, Sean S Brummel, Kumud K Singh, et al.
Annals of Internal Medicine|June 15, 1997
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy TeamM D Hughes, V A Johnson, M S Hirsch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 9, 2020
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110)Diana F Clarke, Edward P Acosta, Mae Cababasay, et al.
Hepatology (Baltimore, Md.)|September 10, 2024
Association of HDV infection and HCC, hepatic decompensation, and all-cause and liver-related death in a national cohortBinu V John, Dustin Bastaich, Mahmoud Manouchehri Amoli, et al.
The Journal of Infectious Diseases|June 25, 2004
Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapyPatricia M Flynn, Bret J Rudy, Steven D Douglas, et al.
Pageof 94